Favorable court ruling for TMC’s Angiomax patent litigation
US drugmaker The Medicines Company (Nasdaq: MDCO) says that the US District Court for the Northern District of Illinois in The Medicines Company v Mylan case entered judgment in favor of TMC on all issues concerning US Patent No 7,582,727 relating to its anticoagulant Angiomax (bivalirudin).
Following a June 2014 trial, Judge Amy St Eve found all of the asserted claims (patent claims 1-3, 7-10, and 17) are infringed by Mylan’s (Nasdaq: MYL) Abbreviated New Drug Application. The same claims were also found to be valid and enforceable.
“We are highly satisfied with the Illinois Court’s ruling, which supports our ongoing conviction to defend these patents vigorously,” said Clive Meanwell, chairman and chief executive at The Medicines Company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze